Alumend focuses on building a product portfolio focused on photochemically activated naphthalimide chemistry in tissue healing and repair. Alumend aims to develop creative solutions for existing underserved markets, by inventing new chemical compounds. Our commitment is to advance these pharmaceutical compounds through research and development of promising new platforms, emphasizing the company's patented core technology.
We have an effective multidisciplinary team of physiologists and chemists, who have expertise in the various fields necessary - and required - to advance an idea from concept to product. This diverse team, with the support of Avera and other world-class collaborations, is positioned to successfully translate novel technologies into a portfolio of clinical products.
Photochemically activated naphthalimide chemistry is a breakthrough in natural tissue repair, providing a safe, effective alternative to more invasive techniques for foreign-body implants. This technology is designed to safely strengthen and bond tissues at a molecular level, making them an excellent choice for a range of medical applications.
Our light-activated naphthalimide platform has been licensed to Alucent as a Peripheral Arterial Disease (PAD) treatment, a disease for which few truly effective treatment options exist.
The light-activated naphthalimides diffuse into tissue, crosslinking proteins to form a strong internal "scaffold" which helps to hold a narrowed artery open. Unlike stents or polymers, our elegantly designed chemical compounds bind naturally with body tissues at the molecular level, creating a truly "natural" environment.
Alumend's mission is to set the standard of care with new clinical therapies based on the research and development of novel chemistries.